retatrutide clinical trials status 2025 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial retatrutide clinical trial south africa – retatrutide clinical trials status 2025

Given the importance of accompanying nutritional and lifestyle support for GLP-1s, treatment and outcome disparities will likely be further magnified by disparities in access to and use of these supports

Genetic variations linked to weight loss, side effects from GLP-1 drugs (Reuters) - Weight-loss responses to GLP-1 obesity drugs, and risks of side effects, may be linked to genetic variants, according to a study conducted by DNA-testing service 23AndMe

In phase 2 diabetes research, retatrutide improved glycaemic control and reduced body weight, and Lillys phase 3 topline results reported HbA1C reductions of around 1.7% to 2.0% at 40 weeks

Both medications are proven and effective